Overview
Indolent multiple myeloma is a subtype of multiple myeloma characterized by a slow progression and prolonged survival without immediate aggressive intervention, often managed with a focus on symptom control and quality of life. 1Diagnosis
Bone marrow biopsy showing clonal plasma cells 1
Serum and urine protein electrophoresis (SPEP/UPEP) with evidence of monoclonal protein 1
Imaging studies (MRI, CT) to assess for bone lesions 1
Minimal anemia, renal insufficiency, or hypercalcemia compared to more aggressive forms 1Management
First-line treatment: Often observation or supportive care, with initiation of therapy based on symptoms or risk factors 1
Drug classes: Use of immunomodulatory drugs (IMiDs) like lenalidomide, proteasome inhibitors (PIs) like bortezomib, or corticosteroids may be considered in selected cases, though specific dosing details are not provided in the abstracts 1
Adjunctive treatments: Focus on managing symptoms such as bone pain, hypercalcemia, and infections 1Special Populations
Elderly: Management often tailored to comorbidities and functional status, with a preference for less intensive regimens 1
Comorbidities: Treatment decisions heavily influenced by coexisting conditions, emphasizing supportive care and symptom management 1Key Recommendations
Incorporate quality of life (QOL) assessments in clinical trials and routine follow-up to guide treatment decisions and patient care (Evidence: Moderate 1)
Consider initiating therapy in indolent multiple myeloma based on symptom burden rather than strict disease progression criteria (Evidence: Expert opinion 1)
Frame treatment outcomes comprehensively, ensuring QOL data is transparently reported and integrated into clinical decision-making (Evidence: Moderate 1)References
1 Milrod CJ, Rubin L, Martinez B, Ollila TA, Olszewski AJ, Pelcovits A. Quality-of-life endpoints collection, reporting, and framing in randomised trials of indolent lymphomas: a systematic review. The Lancet. Haematology 2025. link00032-8)